- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- YJ001 for Spray Use, Placebo of YJ001 for Spray Use
- Drug
- Lead sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fredericksburg, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 15,126
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer-Associated Thrombosis (CAT)
- Interventions
- REGN7508, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- NVA237, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 59
- States / cities
- *See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Interventions
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Wichita, Kansas
- Conditions
- Alzheimer Disease
- Interventions
- BI 409306, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 7
- States / cities
- Orange, California • Sherman Oaks, California • West Palm Beach, Florida + 4 more
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
- Conditions
- Alzheimer's Disease
- Interventions
- BMS-708163, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 30 more
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Interventions
- Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
- Conditions
- Alzheimer's Disease
- Interventions
- Piromelatine 20 mg, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 32
- States / cities
- Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
- Conditions
- Multiple Sclerosis
- Interventions
- 4.5 mg Naltrexone, Naltrexone
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 86 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTI-03, Placebo
- Drug
- Lead sponsor
- Rein Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California
- Conditions
- Tardive Dyskinesia
- Interventions
- SD-809, Placebo
- Drug
- Lead sponsor
- Auspex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 53
- States / cities
- Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 43 more
- Conditions
- Mesenchymal Tumor, Autoimmune Pancreatitis, Lymphoma, Solid Tumors
- Interventions
- EUS-FNB with ProCore needle, EUS-FNB with SharkCore needle, ProCore needle, SharkCore needle
- Procedure · Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- OPN-375, Placebo
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- placebo, PRO283698
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Depemokimab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Bakersfield, California • Modesto, California • Newport Beach, California + 34 more
- Conditions
- Osteoarthritis
- Interventions
- Oxycodone, Placebo, PF-000592379
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more
- Conditions
- Inflammation and Pain Following Ocular Surgery
- Interventions
- Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 6
- States / cities
- Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more
- Conditions
- Burnout, Adverse Event, Medical Education
- Interventions
- Coaching
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 332 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Imsidolimab, Placebo
- Biological
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
- Conditions
- Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
- Interventions
- FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
- Dietary Supplement
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland